作者: Hideaki Kaneto , Yoshihisa Nakatani , Takeshi Miyatsuka , Dan Kawamori , Taka-aki Matsuoka
DOI: 10.1038/NM1111
关键词: Diabetes mellitus 、 Biosynthesis 、 Insulin resistance 、 Pharmacology 、 Transduction (genetics) 、 Cell 、 In vivo 、 Peptide 、 Insulin 、 Internal medicine 、 Endocrinology 、 Medicine
摘要: The JNK pathway is known to be activated in several tissues the diabetic state, and possibly involved development of insulin resistance suppression biosynthesis. Here we show a potential new therapy for diabetes using cell-permeable JNK-inhibitory peptide. Intraperitoneal administration peptide led its transduction into various vivo, this treatment markedly improved ameliorated glucose tolerance mice. These data indicate that critically may have promise as therapeutic agent diabetes.